1. Introduction {#j_med-2018-0065_s_001}
===============

Cervical cancer is the second most common cancer in women all over the world. According to the statistics of the International Agency for Research on Cancer (IARC), the vast majority of new cases of cervical cancer worldwide each year are still in developing countries \[[@j_med-2018-0065_ref_001]\]. Because the survival rates of patients with lymph node metastasis are significantly lower than those without lymph node metastasis \[[@j_med-2018-0065_ref_002]\], an accurate detection of lymph node metastasis of cervical cancer is essential to ensure a proper treatment planning and prognosis for cervical cancer patients \[[@j_med-2018-0065_ref_003]\].

During the development of new radiotracers, the accuracy of Positron-emission tomography (PET) imaging has improved, particularly for antibody-targeted imaging. The oncologists have paid an attention to the field of diagnosis of metastatic lymph nodes by using PET. The principle of PET imaging is that the radioisotopes and other positron-specific radionuclide-labeled basic metabolic substrate accumulate in the lesion, detecting these particular radiation to determine metabolism of lesions. The F18-deoxyglucose is a common radio-labeled drug, which has the characteristics of small radiation, decay fast. F18-deoxyglucose may be injected into a patient, taken up preferentially by abnormal oncologic tissue, and measured using a PET scanner \[[@j_med-2018-0065_ref_004]\]. PET/CT with the advantages of molecular imaging techniques, anatomical and functional characteristics and confirmed diagnostic value in all kinds of solid tumors, PET/CT has been applied in the initial stages of cervical cancer patients, treatment planning, testing and follow-up after treatment and prognostic judgement \[[@j_med-2018-0065_ref_005]\]. In order to objectively evaluate a diagnostic value of PET/CT on lymph node metastasis of cervical cancer, we analyzed the quality of PET/CT in the diagnosis of cervical lymph node metastasis by using systematic review method.

2. Methods {#j_med-2018-0065_s_002}
==========

2.1. Searching method {#j_med-2018-0065_s_002_s_001}
---------------------

We conducted a search of PubMed, Embase, Web of Science, Cochrane Library and Google Scholar databases that were published between 2000 and 2017. We limited the search to study published in English. The medical subject heading terms and keywords used included "lymph node", "PET/CT", "sensitivity", "specificity", "accuracy", and "diagnostic value". Duplicate articles and unpublished studies from international meetings were excluded. The flow diagram of the retrieval process is shown in [Figure 1](#j_med-2018-0065_fig_001){ref-type="fig"}.

![The study selection process](med-13-436-g001){#j_med-2018-0065_fig_001}

2.2. Inclusion criteria {#j_med-2018-0065_s_002_s_002}
-----------------------

Studies were selected carefully on the basis of following criteria: The pathology results as "gold standard", lymph nodes metastases were confirmed by surgery or biopsy; the diagnostic criteria were clear; a case control study (there are 2×2 contingency tables); direct or indirect access to true positive, false positive, false negative, true negative, sensitivity, specificity.

2.3. Excluding standard {#j_med-2018-0065_s_002_s_003}
-----------------------

Non-clinical controlled trials; lack of confirmed evidence by pathological examination; Incomplete data; Case reports; Review literature; Data published repeatedly.

2.4. Data extraction {#j_med-2018-0065_s_002_s_004}
--------------------

Two authors independently assessed each literature, and then downloaded and extracted all the data by using standardized data-abstraction forms. The data extracted included year of publication, true positive, false positive, false negative, true negative, sensitivity, and specificity. For each study, 2×2 contingency tables were constructed. We calculated the sensitivity, specificity, and likelihood ratio (LR).

2.5. Statistical analysis {#j_med-2018-0065_s_002_s_005}
-------------------------

The sensitivity, specificity and 95% confidence interval (CI) of the literature were analyzed by Meta-disc 1.4 software, and the summary receiver operating characteristic (SROC) curves and forest map were drawn. According to the results of heterogeneity test, the corresponding fixed effect model or the random effect model is selected to quantify the effect values.

3. Results {#j_med-2018-0065_s_003}
==========

3.1. Literature search and characteristics of eligible study {#j_med-2018-0065_s_003_s_001}
------------------------------------------------------------

According to search strategy, 27 full articles were finally considered eligible for the review after evaluation. [Figure 1](#j_med-2018-0065_fig_001){ref-type="fig"} shows the flow diagram of study selection process. The detailed characteristics for the 27 eligible studies are summarized in [Table 1](#j_med-2018-0065_tab_001){ref-type="table"}.

###### 

Baseline characteristics of included studies

  Studies                                       Comparisons   Sample   Metastatic positions   TP    FP   FN   TN     SEN    SPE
  --------------------------------------------- ------------- -------- ---------------------- ----- ---- ---- ------ ------ ------
  Loft 2007([@j_med-2018-0065_ref_006])         R             27       Pelvic                 3     1    1    22     75     95.7
  Choi 2006([@j_med-2018-0065_ref_007])         P             22       Pelvic, Para-aortic    10    3    4    5      71.4   62.5
  Choi 2006([@j_med-2018-0065_ref_007])         R             154      Pelvic, Para-aortic    19    9    14   112    57.6   92.6
  Chung 2007([@j_med-2018-0065_ref_008])        P             52       Pelvic                 28    4    3    17     90.3   81.0
  Chung 2010([@j_med-2018-0065_ref_009])        P             83       Pelvic                 8     9    20   46     28.6   83.6
  Chung 2009([@j_med-2018-0065_ref_002])        P             34       Pelvic                 7     1    10   16     41.2   94.1
  Crivellaro 2012([@j_med-2018-0065_ref_010])   P             69       Pelvic                 4     2    11   52     26.7   96.3
  Havrilesky 2003([@j_med-2018-0065_ref_011])   P             29       Para-aortic            12    2    2    13     85.7   86.7
  Kim 2009([@j_med-2018-0065_ref_012])          R             553      Pelvic, Para-aortic    26    30   33   464    44.1   93.9
  Kim 2009([@j_med-2018-0065_ref_012])          P             79       Pelvic, Para-aortic    14    14   16   35     46.7   71.4
  Kitajima 2009([@j_med-2018-0065_ref_013])     R             1976     Pelvic, Para-aortic    23    4    22   1927   51.1   99.8
  Kitajima 2009([@j_med-2018-0065_ref_013])     P             45       Pelvic, Para-aortic    6     3    6    30     50.0   90.9
  Kitajima 2012([@j_med-2018-0065_ref_014])     R             200      Pelvic, Para-aortic    14    6    22   158    38.9   96.3
  Kitajima 2012([@j_med-2018-0065_ref_014])     P             32       Pelvic                 12    2    1    17     92.3   89.5
  Leblanc 2011([@j_med-2018-0065_ref_015])      R             132      Para-aortic            98    6    21   7      82.4   53.8
  Lin 2003([@j_med-2018-0065_ref_016])          P             50       Pelvic, Para-aortic    12    2    2    34     85.7   94.4
  Lv 2014([@j_med-2018-0065_ref_017])           P             87       Pelvic, Para-aortic    34    7    0    46     100    86.8
  Lv 2014([@j_med-2018-0065_ref_017])           R             1163     Pelvic, Para-aortic    61    17   6    1079   91     98.4
  Ma 2003([@j_med-2018-0065_ref_018])           P             104      Pelvic, Para-aortic    38    0    0    66     100    100
  Narayan 2001([@j_med-2018-0065_ref_019])      P             24       Pelvic, Para-aortic    10    1    2    11     83.3   91.7
  Narayan 2001([@j_med-2018-0065_ref_019])      R             24       Pelvic, Para-aortic    4     1    3    16     57.1   94.1
  Nogami 2014([@j_med-2018-0065_ref_020])       R             70       Pelvic, Para-aortic    5     4    10   51     33.3   92.7
  Nogami 2014([@j_med-2018-0065_ref_020])       R             848      Pelvic, Para-aortic    11    9    25   803    30.6   98.9
  Park 2005([@j_med-2018-0065_ref_021])         P             36       Pelvic                 6     8    0    22     100    73.3
  Park 2005([@j_med-2018-0065_ref_021])         R             72       Pelvic                 9     13   0    50     100    79.4
  Reinhardt 2001([@j_med-2018-0065_ref_022])    P             35       Pelvic                 10    1    0    24     100    96
  Reinhardt 2001([@j_med-2018-0065_ref_022])    R             292      Pelvic                 17    4    2    269    89.5   98.5
  Roh 2005([@j_med-2018-0065_ref_023])          R             72       Pelvic                 9     0    13   50     40.9   100
  Roh 2005([@j_med-2018-0065_ref_023])          P             36       Pelvic                 6     0    8    22     42.9   100
  Rose 1999([@j_med-2018-0065_ref_024])         P             16       Para-aortic            11    0    0    5      100    100
  Ryu 2003([@j_med-2018-0065_ref_025])          P             249      Para-aortic            28    52   3    166    90.3   76.1
  Sandvik 2011([@j_med-2018-0065_ref_026])      P             36       Pelvic                 1     3    4    28     20.0   90.3
  Signorelli 2011([@j_med-2018-0065_ref_027])   P             159      Pelvic                 127   9    4    19     96.9   67.9
  Sironi 2006([@j_med-2018-0065_ref_028])       P             48       Pelvic, Para-aortic    11    5    1    31     91.7   86.1
  Sironi 2006([@j_med-2018-0065_ref_028])       R             1081     Pelvic                 13    3    5    1060   72.2   99.7
  Stecco 2016([@j_med-2018-0065_ref_029])       P             27       Pelvic                 7     3    1    16     87.5   84.2
  Stecco 2016([@j_med-2018-0065_ref_029])       R             216      Pelvic                 26    17   11   162    70.3   90.5
  Belhocine 2002([@j_med-2018-0065_ref_030])    P             217      Pelvic, Para-aortic    19    3    8    187    70.4   98.4
  Yeh 2002([@j_med-2018-0065_ref_031])          P             42       Pelvic                 10    2    1    29     90.9   93.5
  Yildirim 2008([@j_med-2018-0065_ref_032])     R             16       Pelvic                 2     2    2    10     50.0   83.3

3.2. Quality assessment {#j_med-2018-0065_s_003_s_002}
-----------------------

We assessed the quality of included studies according to QUADAS. Each study was respectively evaluated by two independent investigators. On average, the investigators disagreed on 3 of 11 items (range, 0--6). All disagreements were resolved by consensus.

3.3. The diagnostic sensitivity and specificity of PET/CT {#j_med-2018-0065_s_003_s_003}
---------------------------------------------------------

The pooled diagnostic sensitivity and specificity of PET/CT are 0.72 (95% CI, \[0.69, 0.75\]), 0.96 (95% CI, \[0.96, 0.97\]), respectively. Significant heterogeneity was found among these studies (I^2^=88.6% and 93.0%). Due to significant heterogeneity of the data, we used a random effects model ([Figure 2](#j_med-2018-0065_fig_002){ref-type="fig"} and [3](#j_med-2018-0065_fig_003){ref-type="fig"}).

![The plot for the sensitivity of PET/CT](med-13-436-g002){#j_med-2018-0065_fig_002}

![The plot for the specificity of PET/CT](med-13-436-g003){#j_med-2018-0065_fig_003}

3.4. The negative LR, positive LR and SROC curve of PET/CT {#j_med-2018-0065_s_003_s_004}
----------------------------------------------------------

The pooled negative LR and positive LR of PET/CT are 0.34 (95% CI, \[0.27, 0.44\]), 9.12 (95% CI, \[6.19, 13.45\]), respectively ([Figure 4](#j_med-2018-0065_fig_004){ref-type="fig"} and [5](#j_med-2018-0065_fig_005){ref-type="fig"}). We successfully plotted the SROC curve. The area under the SROC curve (AUC) is 0.93 and the Q\* is 0.86 ([Figure 6](#j_med-2018-0065_fig_006){ref-type="fig"}).

![The plot for the negative LR of PET/CT](med-13-436-g004){#j_med-2018-0065_fig_004}

![The plot for the positive LR of PET/CT](med-13-436-g005){#j_med-2018-0065_fig_005}

![The SROC curve of PET/CT](med-13-436-g006){#j_med-2018-0065_fig_006}

3.5. Subgroup analysis {#j_med-2018-0065_s_003_s_005}
----------------------

Subgroup analysis showed that the performance of PET/CT in detecting the lymph nodes metastases in patient-based unit, the pooled diagnostic sensitivity and specificity are 0.80 (95% CI, \[0.76, 0.83\]), 0.87 (95% CI, \[0.84, 0.89\]), respectively. In region-based unit, the pooled diagnostic sensitivity and specificity are 0.64 (95% CI, \[0.60, 0.68\]), 0.98 (95% CI, \[0.98, 0.98\]), respectively. Meta-analysis results are shown in [Table 2](#j_med-2018-0065_tab_002){ref-type="table"}.

###### 

Subgroup analysis of pooled sensitivity, specificity, likelihood ratio

  Subgroup                        SEN (95%CI)       SPE (95%CI)       +LR (95%CI)         -LR (95%CI)
  ------------------------------- ----------------- ----------------- ------------------- ------------------
  Analysis units                                                                          
  Patient-based (n=24)            0.80(0.76-0.83)   0.87(0.84-0.89)   5.62(3.84--8.22)    0.24(0.15-0.39)
  Region-specific (n=16)          0.64(0.60-0.68)   0.98(0.98-0.98)   15.60(7.73-31.48)   0.43(0.33-0.56)
  Metastatic positions                                                                    
  Pelvic (n=19)                   0.76(0.71-0.80)   0.96(0.95-0.97)   8.36(4.92--14.18)   0.31(0.20--0.48)
  Para-aortic (n=4)               0.85(0.79-0.90)   0.76(0.70-0.81)   3.33(1.85-5.98)     0.18(0.08-0.42)
  Pelvic and Para-aortic (n=17)   0.65(0.60-0.69)   0.98(0.97-0.98)   12.03(6.20-23.37)   0.40(0.29-0.55)

4. Discussion {#j_med-2018-0065_s_004}
=============

Cervical cancer is the third most common malignant tumor in women worldwide after breast cancer and colorectal cancer. With younger onset age, the increase of its incidence and recurrence rate after treatment, cervical cancer becomes significantly more influential on women's health. Thus, a diagnosis of lymph node metastasis as early as possible has an important clinical significance. This systematic review included 27 studies of PET/CT for the diagnosis of cervical lymph node metastasis with surgical pathology as a reference standard. The data showed that the diagnosis of cervical lymph node metastasis with moderate sensitivity and specificity can be used as one of the effective diagnostic methods of cervical lymph node metastasis.

To reduce heterogeneity, we performed a subgroup analysis. The result of subgroup analysis showed that the patient-based analysis unit had a higher sensitivity than the lymph node analysis unit, suggesting that cervical lymph node metastasis of suspected cases can be effectively screened when PET/CT diagnosis is positive. The lymph node as the unit of analysis compared with the patient as the unit of analysis has a higher specificity, likelihood ratio, the negative likelihood ratio, indicating that it can effectively rule out cases of cervical lymph node metastasis when the PET/CT diagnosis is negative.

The quality of results evaluated in this systematic review proved to be insubstantial. Due to the low quality research and literature included being based mostly on the retrospective studies, there may be inherent choice bias. There was a large heterogeneity in this study. The combined analysis showed that I^2^ was more than 50%, the reason may be due to inconsistencies in criteria of interpretation of PET/CT. In the process of literature filtering we found: ([@j_med-2018-0065_ref_001]) most of the research in measuring results without using the blind method. Possible interpretation bias; ([@j_med-2018-0065_ref_002]) most of the literature does not report the sensitivity and specificity; these problems will inevitably affect the quality of the literature and combined analysis.

In summary, PET/CT in the diagnosis of pelvic lymph node metastasis in cervical cancer ability has a moderate sensitivity and high specificity. The results will help us to accurately evaluate the preoperative cervical cancer patients.
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